Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV | Zendy

David Del Bello | Zendy; Agnes Cha | Zendy; Maria Sorbera | Zendy; Kian Bichoupan | Zendy; Calley Levine | Zendy; Erin Doyle | Zendy; Alyson Harty | Zendy; Neal M. Patel | Zendy; Michel Ng | Zendy; Donald Gardenier | Zendy; Joseph A. Odin | Zendy; Thomas D. Schiano | Zendy; Daniel S. Fierer | Zendy; Leonard Berkowitz | Zendy; Ponni V. Perumalswami | Zendy; Douglas T. Dieterich | Zendy; Andrea D. Branch | Zendy

Open Access

Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV

Author(s) -

David Del Bello,

Agnes Cha,

Maria Sorbera,

Kian Bichoupan,

Calley Levine,

Erin Doyle,

Alyson Harty,

Neal M. Patel,

Michel Ng,

Donald Gardenier,

Joseph A. Odin,

Thomas D. Schiano,

Daniel S. Fierer,

Leonard Berkowitz,

Ponni V. Perumalswami,

Douglas T. Dieterich,

Andrea D. Branch

Publication year - 2016

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1093/cid/ciw119

Subject(s) - medicine , sofosbuvir , simeprevir , regimen , adverse effect , hepatitis c , hepatitis c virus , ribavirin , rash , virology , virus

Patients with hepatitis C virus (HCV) with or without human immunodeficiency virus (HIV) achieve high sustained virological response (SVR) rates on sofosbuvir (SOF)-containing regimens in clinical trials. Real world data on patients coinfected with HCV and HIV treated with SOF-based regimens are lacking.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research